CN107296264A - 预防及治疗高血脂、脂肪肝的大鲵油脂食品及其制备方法 - Google Patents
预防及治疗高血脂、脂肪肝的大鲵油脂食品及其制备方法 Download PDFInfo
- Publication number
- CN107296264A CN107296264A CN201610240897.4A CN201610240897A CN107296264A CN 107296264 A CN107296264 A CN 107296264A CN 201610240897 A CN201610240897 A CN 201610240897A CN 107296264 A CN107296264 A CN 107296264A
- Authority
- CN
- China
- Prior art keywords
- powder
- giant salamander
- blood
- fatty
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000157862 Dicamptodontidae Species 0.000 title claims abstract description 28
- 210000004369 blood Anatomy 0.000 title claims abstract description 26
- 239000008280 blood Substances 0.000 title claims abstract description 26
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 22
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 22
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 22
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 22
- 230000002265 prevention Effects 0.000 title claims abstract description 14
- 235000021149 fatty food Nutrition 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 55
- CAXNYFPECZCGFK-UHFFFAOYSA-N 2-phenyl-2-pyridin-2-ylacetonitrile Chemical compound C=1C=CC=NC=1C(C#N)C1=CC=CC=C1 CAXNYFPECZCGFK-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000013312 flour Nutrition 0.000 claims abstract description 15
- 241000209140 Triticum Species 0.000 claims abstract description 12
- 235000021307 Triticum Nutrition 0.000 claims abstract description 12
- 230000007062 hydrolysis Effects 0.000 claims abstract description 12
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 12
- 244000017020 Ipomoea batatas Species 0.000 claims abstract description 11
- 235000002678 Ipomoea batatas Nutrition 0.000 claims abstract description 11
- 244000062793 Sorghum vulgare Species 0.000 claims abstract description 11
- 240000008042 Zea mays Species 0.000 claims abstract description 11
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 11
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 11
- 235000005822 corn Nutrition 0.000 claims abstract description 11
- 235000019713 millet Nutrition 0.000 claims abstract description 11
- 239000005030 aluminium foil Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims 1
- 239000003814 drug Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000009835 boiling Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000009461 vacuum packaging Methods 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000193587 Moonvirus Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- -1 coacetylase Chemical compound 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- SEBFKMXJBCUCAI-DBMPWETRSA-N silybin Chemical compound C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-DBMPWETRSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229940054870 urso Drugs 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种预防及治疗高血脂、脂肪肝的大鲵油脂食品,由以下原料混合均匀而成:燕麦片粉、大豆蛋白粉、膨化玉米粉、膨化小米粉、水解红薯粉和水解小麦胚芽粉中任意一种粉20‑40克;大鲵油2.5‑10毫升;其制备方法,包括以下步骤:(1)选取食料:选取燕麦片粉、大豆蛋白粉、膨化玉米粉、膨化小米粉、水解红薯粉和水解小麦胚芽粉为食料;(2)混合:取步骤(1)中任意一种粉20‑40克,加入2.5‑10毫升大鲵油,并混合均匀;(3)包装:铝箔袋真空包装。
Description
技术领域
本发明涉及保健食品,尤其涉及一种预防及治疗高血脂、脂肪肝的大鲵油脂食品及其制备方法。
背景技术
高脂血症可分为原发性和继发性两类。原发性与先天性和遗传有关,继发性多发生于代谢性紊乱疾病如糖尿病、高血压有关,或与其他因素年龄、性别、季节、饮酒、吸烟、饮食、体力活动、精神紧张、情绪活动等有关。通常情况下,多数患者并无明显症状和异常体征。不少人是由于其他原因进行血液生化检验时才发现有血浆脂蛋白水平升高。血浆总胆固醇浓度>5.17mmol/L(200mg/dl)可定为高胆固醇血症,血浆三酰甘油浓度>2.3mmol/L(200mg/dl)为高三酰甘油血症。
高血脂的治疗:一般治疗有控制理想体重,运动锻炼,戒烟,饮食治疗。药物治疗以降低血清总胆固醇和LDL胆固醇为主的有他汀类和树脂类。以降低血清三酰甘油为主的药物有贝特类和烟酸类。服药后部分病人可出现脸部潮红皮肤瘙痒或胃部灼热感上腹部不适和轻微头痛。长期应用贝特类药物可能诱发类似I型自身免疫性慢性肝炎。非诺贝特可引起肝功异常。控制高血脂往往是一个长期的过程,患者使用药物控制血脂会出现服药时血脂正常,停药反弹。血脂忽高忽低反复,患者在忍受降脂药副作用同时担心停药后血脂升高,因此患者服用降脂药依从性普遍差,致使好多高血脂患者害怕血脂异常对身体的伤害,同时又对控制血脂无可奈何。
脂肪肝,由于各种原因引起的肝细胞内脂肪堆积过多的病变。正严重威胁人类的健康,成为仅次于病毒性肝炎的第二大肝病,已被公认为隐蔽性肝硬化的常见原因。脂肪肝是一种常见的临床现象,而非一种独立的疾病。可分为肥胖性,糖尿病脂肪肝,药物性脂肪肝,妊娠脂肪肝,其他疾病引起的脂肪肝。其临床表现轻者无症状,仅有疲乏感。重者病情凶猛,可导致肝硬化等其他疾病。
1.一般治疗:找出病因,调整饮食结构,适当增加运动,补硒。2.药物治疗:到目前为止,西药尚无防治脂肪肝的有效药物,以中药长期调理性的治疗较好。西药常选用保护肝细胞、去脂药物及抗氧化剂等,如维生素B、C、E,卵磷脂、熊去氧胆酸、水飞蓟素、肌苷、辅酶A、还原型谷胱甘肽、牛磺酸、肉毒碱乳清酸盐、肝泰乐,以及某些降脂药物等。这些药物只是一些调理,补益制剂,疗效不肯定。因此尽管脂肪肝是一个对机体有极大危害性疾病,且患病率高,但就目前医学现状而论还没有一个很有效的治疗方法。
我在大鲵繁育研究中解刨亲本时发现,大鲵与其它动物脂肪聚积分布有明显不同。猪、牛、鸡、鸭、鱼等动物、禽类和鱼类,它们积累的脂肪(乳白色、微黄色)分布于全身,腹腔内积累的乳白色块状或网状脂肪特别多,而大鲵的脂肪(黄色)主要聚积于尾部,腹腔内(肠道、肝脏、腹腔壁等)和躯干部目测几乎看不见块状或网状的脂肪。这种奇特的现象引发我对大鲵脂肪的进一步研究和临床实验。
资料显示:大鲵油主要含12种脂肪酸:C18:124.55%、C16:116.40%、C16:015.64%、C18:28.28%、C20:56.74%、C18:35.48%、C22:64.27%、C14:03.00%、C18:02.87%、C20:42.71%、C22:52.64%、C17:02.47%。饱和脂肪酸(SFA)达23.98%,不饱和脂肪酸(UFA)达76.58%,其中单不饱和脂肪酸(MUFA)为45.47%,多不饱和脂肪酸(PUFA)为31.11%,UFA∶SFA=3.19∶1(m/m),ω-3型PUFA为20.85%,ω-6型PUFA为10.26%。实验结果表明大鲵油富含ω-3和ω-6型PUFA,极具营养和保健功能。
发明内容
本发明是为了解决上述不足,提供了一种预防及治疗高血脂、脂肪肝的大鲵油脂食品及其制备方法。
本发明的上述目的通过以下的技术方案来实现:
一种预防及治疗高血脂、脂肪肝的大鲵油脂食品,其特征在于:由以下原料混合均匀而成:燕麦片粉、大豆蛋白粉、膨化玉米粉、膨化小米粉、水解红薯粉和水解小麦胚芽粉中任意一种粉20-40克;大鲵油2.5-10毫升。
一种预防及治疗高血脂、脂肪肝的大鲵油脂食品的制备方法,其特征在于:包括以下步骤:
(1)选取食料:选取燕麦片粉、大豆蛋白粉、膨化玉米粉、膨化小米粉、水解红薯粉和水解小麦胚芽粉为食料;
(2)混合:取步骤(1)中任意一种粉20-40克,加入2.5-10毫升大鲵油,并混合均匀;
(3)包装:铝箔袋真空包装。
使用时,每天早上或晚上开水冲泡食用一袋,对预防高血脂有较好的作用。因是纯天然食料长期服用对人体无任何副作用。
本发明与现有技术相比的优点是:通过食用本发明方法制备的大鲵油脂保健食品,能够对预防及治疗高血脂、脂肪肝有显著效果,且长期服用对人体无任何副作用。
具体实施方式
下面结合实施例对本发明进一步详述。
一种预防及治疗高血脂、脂肪肝的大鲵油脂食品,由以下原料混合均匀而成:燕麦片粉、大豆蛋白粉、膨化玉米粉、膨化小米粉、水解红薯粉和水解小麦胚芽粉中任意一种粉20-40克;大鲵油2.5-10毫升。其制备方法,包括以下步骤:(1)选取食料:选取燕麦片粉、大豆蛋白粉、膨化玉米粉、膨化小米粉、水解红薯粉和水解小麦胚芽粉为食料;(2)混合:取步骤(1)中任意一种粉20-40克,加入2.5-10毫升大鲵油,并混合均匀;(3)包装:铝箔袋真空包装。
实施例1:高血脂预防保健型:选取燕麦片粉、大豆蛋白粉、膨化玉米粉、膨化小米粉、水解红薯粉和水解小麦胚芽粉为食料;取其中任意一种粉20克,加入2.5毫升大鲵油混合均匀,铝箔袋真空包装。每天早上或晚上开水冲泡食用一袋,对预防高血脂有较好的作用。因是纯天然食料长期服用对人体无任何副作用。
实施例2:高血脂治疗型:选取燕麦片粉、大豆蛋白粉、膨化玉米粉、膨化小米粉、水解红薯粉和水解小麦胚芽粉为食料;取其中任意一种粉40克,加入10毫升大鲵油混合均匀,铝箔袋真空包装。每天早上或晚上开水冲泡食用一袋,对严重高血脂有较好的治疗作用,痛风患者慎用以大豆蛋白粉为辅料的冲剂。
实例:马某:男,63岁,家住什邡市,宏达集团退休工人。曾患胰腺炎,且血脂非常高。2013年2月,血清检测,甘油三酯23.19是正常标准的10倍,总胆固醇11.78是正常标准的两倍。同年2月开始按标准服用以上治疗型冲剂,一月后指标开始下降,到2015年12月,甘油三酯下降至4.44略高于正常标准,总胆固醇4.97已恢复正常。头痛、头晕等症状消失。
实例:毛某:男,59岁,家住德阳市,龙蟒集团干部。血脂较高,一直在服用降脂药物,2015年6月,血清检测,甘油三酯2.63高于标准近一倍,总胆固醇正常。同年7月开始按标准服用以上治疗型冲剂,同时停止服用降脂药物。2015年9月,甘油三酯下降至1.9略高于正常标准,总胆固醇6.18略高于正常标准。
实施例3:脂肪肝预防保健型:选取燕麦片粉、大豆蛋白粉、膨化玉米粉、膨化小米粉、水解红薯粉和水解小麦胚芽粉为食料;取其中任意一种粉20克,加入1至2.5毫升大鲵油混合均匀,铝箔袋真空包装。开水冲泡食用,每天早晚各一袋,对预防脂肪肝有较好的作用,痛风患者慎用以大豆蛋白粉为辅料的冲剂。因是天然的长期服用对人体无任何副作用。
实施例4:脂肪肝治疗型:选取燕麦片粉、大豆蛋白粉、膨化玉米粉、膨化小米粉、水解红薯粉和水解小麦胚芽粉为食料;取其中任意一种粉20克,加入2.5至5毫升大鲵油混合均匀,铝箔袋真空包装。开水冲泡食用,每天早晚各一袋,对严重脂肪肝有较好的治疗作用,痛风患者慎用以大豆蛋白粉为辅料的冲剂。截至目前数十名患者临床实验其有效率达100%,而且是天然油脂对人体无任何副作用。
实例:高某,男、52岁,家住什邡市,公司老总。2015年8月在什邡宏大医院彩超检查,有较强的回声。经多名医生会诊,排除病变,最终确定为非均匀性脂肪肝且较严重。同年8月开始按标准服用以上治疗型冲剂,2016年2月经什邡宏大医院彩超检查,回声明显减弱,已接近肝脏正常组织的回声,且身体自我感觉特别良好。
实例:邓某,女、54岁,家住什邡市,什邡市人民医院医生。患脂肪肝多年,同时还是肺癌患者,2015年5月血浆检测,谷丙转氨酶(ALT)54较高,同年5月开始按标准服用以上治疗型冲剂,2015年12月经血浆检测ALT降至34正常。
实例:谭某,男,52岁,家住什邡市,蓝剑饮品集团片区老总。患脂肪肝多年,2015年12月血清检测,谷丙转氨酶(ALT)59较高,同年12月开始按标准服用以上治疗型冲剂,2016年3月血清检测谷丙转氨酶(ALT)降至32.1正常。
以上所述仅为本发明的实施例,并非因此限制本发明的专利范围,凡是利用本发明说明书及实施例内容所作的等效结构或等效流程变换,或直接或间接运用在其他相关的技术领域,均同理包括在本发明的专利保护范围内。
Claims (2)
1.一种预防及治疗高血脂、脂肪肝的大鲵油脂食品,其特征在于:由以下原料混合均匀而成:燕麦片粉、大豆蛋白粉、膨化玉米粉、膨化小米粉、水解红薯粉和水解小麦胚芽粉中任意一种粉20-40克;大鲵油2.5-10毫升。
2.一种预防及治疗高血脂、脂肪肝的大鲵油脂食品的制备方法,其特征在于:包括以下步骤:
(1)选取食料:选取燕麦片粉、大豆蛋白粉、膨化玉米粉、膨化小米粉、水解红薯粉和水解小麦胚芽粉为食料;
(2)混合:取步骤(1)中任意一种粉20-40克,加入2.5-10毫升大鲵油,并混合均匀;
(3)包装:铝箔袋真空包装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610240897.4A CN107296264A (zh) | 2016-04-14 | 2016-04-14 | 预防及治疗高血脂、脂肪肝的大鲵油脂食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610240897.4A CN107296264A (zh) | 2016-04-14 | 2016-04-14 | 预防及治疗高血脂、脂肪肝的大鲵油脂食品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107296264A true CN107296264A (zh) | 2017-10-27 |
Family
ID=60137920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610240897.4A Pending CN107296264A (zh) | 2016-04-14 | 2016-04-14 | 预防及治疗高血脂、脂肪肝的大鲵油脂食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107296264A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238727B2 (en) * | 2000-10-13 | 2007-07-03 | Chugai Seiyaku Kabushiki Kaisha | Compositions for improving lipid metabolism |
CN101653211A (zh) * | 2009-08-27 | 2010-02-24 | 杨波 | 一种适宜肥胖患者食用的面粉 |
CN101721432A (zh) * | 2009-12-10 | 2010-06-09 | 张家界金鲵生物科技有限公司 | 一种大鲵油软胶囊、制备方法及其用途 |
CN101869129A (zh) * | 2010-06-02 | 2010-10-27 | 李革田 | 营养粮粉 |
CN103349193A (zh) * | 2013-06-01 | 2013-10-16 | 张家界金鲵生物工程股份有限公司 | 一种大鲵营养粉及其生产方法 |
CN103666742A (zh) * | 2013-11-28 | 2014-03-26 | 张家界金鲵生物工程股份有限公司 | 一种大鲵油的提取方法及其产品 |
CN104172196A (zh) * | 2014-07-30 | 2014-12-03 | 广州施健生物科技有限公司 | 一种用于预防及改善脂肪肝的营养组合物及其制备方法 |
KR20150117185A (ko) * | 2014-04-09 | 2015-10-19 | 고려대학교 산학협력단 | 다이펩티드 we 또는 wr을 유효성분으로 함유하는 지질대사 개선 및 지방축적 억제용 조성물 |
CN105124566A (zh) * | 2015-06-09 | 2015-12-09 | 汉中领维生物科技发展有限公司 | 大鲵油、杜仲籽油和红曲米、山楂果、红茶提取物的混合物软胶囊制备及保健作用 |
-
2016
- 2016-04-14 CN CN201610240897.4A patent/CN107296264A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238727B2 (en) * | 2000-10-13 | 2007-07-03 | Chugai Seiyaku Kabushiki Kaisha | Compositions for improving lipid metabolism |
CN101653211A (zh) * | 2009-08-27 | 2010-02-24 | 杨波 | 一种适宜肥胖患者食用的面粉 |
CN101721432A (zh) * | 2009-12-10 | 2010-06-09 | 张家界金鲵生物科技有限公司 | 一种大鲵油软胶囊、制备方法及其用途 |
CN101869129A (zh) * | 2010-06-02 | 2010-10-27 | 李革田 | 营养粮粉 |
CN103349193A (zh) * | 2013-06-01 | 2013-10-16 | 张家界金鲵生物工程股份有限公司 | 一种大鲵营养粉及其生产方法 |
CN103666742A (zh) * | 2013-11-28 | 2014-03-26 | 张家界金鲵生物工程股份有限公司 | 一种大鲵油的提取方法及其产品 |
KR20150117185A (ko) * | 2014-04-09 | 2015-10-19 | 고려대학교 산학협력단 | 다이펩티드 we 또는 wr을 유효성분으로 함유하는 지질대사 개선 및 지방축적 억제용 조성물 |
CN104172196A (zh) * | 2014-07-30 | 2014-12-03 | 广州施健生物科技有限公司 | 一种用于预防及改善脂肪肝的营养组合物及其制备方法 |
CN105124566A (zh) * | 2015-06-09 | 2015-12-09 | 汉中领维生物科技发展有限公司 | 大鲵油、杜仲籽油和红曲米、山楂果、红茶提取物的混合物软胶囊制备及保健作用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fetterman Jr et al. | Therapeutic potential of n-3 polyunsaturated fatty acids in disease | |
Leventhal et al. | Treatment of rheumatoid arthritis with gammalinolenic acid | |
US20090011012A1 (en) | Fatty acid compositions and methods of use | |
US20120277316A1 (en) | Methods and compositions for treating and preventing parenteral nutrition associated liver disease | |
CN109689039A (zh) | 用于预防或改善痴呆症或抑郁状态的组合物 | |
CA2844811A1 (en) | Methods for weight loss and ketogenic compositions | |
JP2020510678A (ja) | 対象におけるマイトファジーを改善するための方法 | |
JP2007254440A (ja) | 脂質代謝調節剤及び脂質代謝調節食品 | |
JP2019182881A (ja) | 末梢神経障害の予防又は改善用組成物 | |
JP5718293B2 (ja) | Gip上昇抑制剤 | |
Bays et al. | The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels | |
IT201900003013A1 (it) | Regime di somministrazione di composizioni di ormone tiroideo T4 con elevato assorbimento orale | |
CN107296264A (zh) | 预防及治疗高血脂、脂肪肝的大鲵油脂食品及其制备方法 | |
JPH09201A (ja) | 炎症性腸疾患用食品 | |
US20160114002A1 (en) | Compositions comprising plant proteins and methods for prevention of metabolic and cardiovascular pathologies in patient with cardiometabolic risk, including hyperglycemia | |
JP7294147B2 (ja) | 侵害受容性疼痛の予防又は改善用組成物 | |
JP2007230987A (ja) | 抗肥満剤 | |
Aziz et al. | Combating Metabolic Syndrome through Non-Pharmacological Strategies: A Literature Review: Combating Metabolic Syndrome | |
CN106727480A (zh) | Fex-3在制备抗肥胖症药物中的应用 | |
JP2007161703A (ja) | 抗疲労作用化合物および持久力増強作用化合物及びそれを含有する飲食品 | |
CN107372861A (zh) | 一种组合物及其在制备改善高血脂症的产品中的应用 | |
Lee | A flood of health functional foods: what is to be recommended? | |
Halpern | The Inflammation Revolution: A Natural Solution for Arthritis, Asthma & Other Inflammatory Disorders | |
WO2020052742A1 (en) | Capsule, tablet or pill | |
BR112019012741A2 (pt) | composição, formulação, método para prevenir e/ou tratar caquexia em um indivíduo, uso da composição, e, produto de uso médico especial, produto de alimentos para uso específico de saúde, produto para alimentos para fins médicos especiais, produto de alimento para uso dietético especial, produto de nutrição médica e produto de alimento médico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171027 |
|
RJ01 | Rejection of invention patent application after publication |